Vascular Sensitivity to Adrenergic Agonists in Patients With CHF and in Healthy Subjects

This study is ongoing, but not recruiting participants.

Sponsored by:	Hadassah Medical Organization
Information provided by:	Hadassah Medical Organization
ClinicalTrials.gov Identifier:	NCT00782782

Purpose

Congestive Heart failure (CHF) is asociated with changes in cardiac function and vascular responses. The aim of this study is to characterize these differences. Our hypothesis is, that there are differences in vascular responses between healthy subjects and patients with CHF.

Condition
Congestive Heart Failure

MedlinePlus related topics: Heart Failure

U.S. FDA Resources

Study Type:	Observational
Study Design:	Case Control, Prospective
Official Title:	Effect of Medications on Vascular Response in Patients With CHF and in Healthy Subjects

Further study details as provided by Hadassah Medical Organization:

Primary Outcome Measures:

vascular sensitivity (ED50) and response (Emax) to dexmedetomidine, phenylephrine, isoproterenol and terbutaline [ Time Frame: 3 weeks ] [ Designated as safety issue: No ]

Biospecimen Retention: Samples Without DNA

Biospecimen Description:

samples for norepinephrine and PRA will be retained

Estimated Enrollment:	80
Study Start Date:	August 2008
Estimated Study Completion Date:	December 2011
Estimated Primary Completion Date:	December 2009 (Final data collection date for primary outcome measure)

Eligibility

Ages Eligible for Study:	18 Years to 70 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes
Sampling Method:	Non-Probability Sample

Study Population

Patients with congestive heart failure NYHA I-II and healthy subjects

Criteria

Inclusion Criteria:

Patients with congestive heart failure NYHA I-II
Stable clinical condition

Exclusion Criteria:

Resting systolic blood pressure < 100
Resting heart rate < 50
Hypersensitivity to dexmedetomidine, phenylephrine, isoproterenol, terbutaline

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00782782

Locations

Israel
Hadassah University Hospital
Jerusalem, Israel, 92110

Sponsors and Collaborators

Hadassah Medical Organization

Investigators

Principal Investigator:

Mordechai Muszkat

Hadassah University Hospital

More Information

Responsible Party:	Hadassah University Hospital ( Mordechai Muszkat )
Study ID Numbers:	366-28.12.07
Study First Received:	October 26, 2008
Last Updated:	October 28, 2008
ClinicalTrials.gov Identifier:	NCT00782782
Health Authority:	Israel: Ministry of Health

Study placed in the following topic categories:

Heart Failure
Heart Diseases
Healthy

Additional relevant MeSH terms:

Cardiovascular Diseases

ClinicalTrials.gov processed this record on January 16, 2009